Weider confident in future of joint care

By Staff Reporter

- Last updated on GMT

Related tags: Revenue

Joint health continues to be a major growth area for Weider
Nutrition International, which yesterday reported a 9.8 percent
increase in sales of Q1 2006 driven by joint care brands.

Net sales for the company (doing business as Schiff Nutrition) were $48 million for the quarter, up from $43.7 million for the same period of last year. Its branded products alone increased 16.9 percent, thanks largely to the Move Free joint care brand.

But although net income was up 33 percent to $4.99 million, income from operations dropped to $3.77 million, from $4.96m last year.

"As expected, we experienced an erosion in our gross margin primarily due to the ongoing higher raw material costs in a price competitive market,"​ said president and CEO Bruce Wood.

The cost of goods sold rose by a disproportionate 31 percent to $35 million, compared to the sales increase.

For companies in the joint health category, glucosamine prices have been a cause for concern in recent times, due to duties imposed on shrimps - the main source of the ingredient - imported from Asia and South America. These made shrimp farming less profitable, causing some farmers to turn away from the business and leading to a shortage.

By the end of 2004, prices were reported to be around four times their level in February of that year - $20 compared to $5.

Wood said that the positive results of the NIH Glucosamin/Chondroitin Arthritis Intervention Trail joint care study were encouraging for the company. "This seminal study, coupled with positive results contained in the abstract from the recently completed European Glucosamine Unum In Die Efficacy Trial, give us reason to remain confident in the long-term potential of the joint care category,"​ he said.

In June, Weider announced the sale of Haleko, Europe's biggest sports nutrition business, to Croatian holding company Atlantic Grupa for around $15 million - a transaction that left the Utah company's interest in Europe "pretty minimal".

But chief financial officer Joseph Baty told NutraIngredients-USA.com that it is interested in acquisitions that "complement the Schiff business and are clearly synergistic with ongoing operations and marketing strategies".

As of August 31, Weider had short term cash and cash equivalents of $21.2 million - almost double the $11.36 it had at the same point last year. It had also reduced its short term debt from $3.02 million to $0.25 million.

Related topics: Bone & joint health

Related news

Show more

Related products

show more

Proven Efficacy of Delphinol® on Bone Health

Proven Efficacy of Delphinol® on Bone Health

Anklam Extrakt GmbH | 21-Oct-2019 | Research Study

Within the course of a preclinical study covering in vitro and in vivo analyses, the effect of a polyphenol-rich maqui berry extract (Delphinol®) on bone...

MenaQ7® Partners Benefit From K2 Outreach

MenaQ7® Partners Benefit From K2 Outreach

NattoPharma USA, Inc. | 22-Apr-2019 | Case Study

MenaQ7® K2 as MK-7 provides health benefits for all ages. That is a fact clinically proven by NattoPharma and communicated to practitioners and consumers...

GlycOmega™-PLUS: Beyond Greenshell™ mussel powder

GlycOmega™-PLUS: Beyond Greenshell™ mussel powder

LEHVOSS Nutrition | 04-Feb-2019 | Technical / White Paper

From Aroma NZ Ltd, GlycOmega™ PLUS is the new generation of Greenshell™ mussel meat extract, which LEHVOSS Nutrition is pleased to add to the Gee Lawson...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars